These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 10146993)

  • 1. Zidovudine: a review of pharmacoeconomic and quality-of-life considerations for its use in patients with human immunodeficiency virus.
    Langtry HD; Palmer KJ; Benfield P
    Pharmacoeconomics; 1993 Apr; 3(4):309-37. PubMed ID: 10146993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost effectiveness analysis of early zidovudine treatment of HIV infected patients.
    Oddone EZ; Cowper P; Hamilton JD; Matchar DB; Hartigan P; Samsa G; Simberkoff M; Feussner JR
    BMJ; 1993 Nov; 307(6915):1322-5. PubMed ID: 8257887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of short-course zidovudine to prevent perinatal HIV type 1 infection in a sub-Saharan African Developing country setting.
    Mansergh G; Haddix AC; Steketee RW; Nieburg PI; Hu DJ; Simonds RJ; Rogers M
    JAMA; 1996 Jul; 276(2):139-45. PubMed ID: 8656506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advanced HIV infection treated with zidovudine monotherapy: lifetime values of absolute cost-effectiveness as a pharmacoeconomic reference for future studies evaluating antiretroviral combination treatments. The Osservatorio SIFO sui Farmaci.
    Messori A; Becagli P; Berto V; Trippoli S; Font M; Tosolini F; Venturini F; Martini N
    Ann Pharmacother; 1997 Dec; 31(12):1447-54. PubMed ID: 9416379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic impact of treatment of HIV-positive pregnant women and their newborns with zidovudine. Implications for HIV screening.
    Mauskopf JA; Paul JE; Wichman DS; White AD; Tilson HH
    JAMA; 1996 Jul; 276(2):132-8. PubMed ID: 8656505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of chemoprophylaxis after occupational exposure to HIV.
    Pinkerton SD; Holtgrave DR; Pinkerton HJ
    Arch Intern Med; 1997 Sep; 157(17):1972-80. PubMed ID: 9308509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost effectiveness of low-dose zidovudine therapy for asymptomatic patients with human immunodeficiency virus (HIV) infection.
    Schulman KA; Lynn LA; Glick HA; Eisenberg JM
    Ann Intern Med; 1991 May; 114(9):798-802. PubMed ID: 1672806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of prophylactic AZT following needlestick injury in health care workers.
    Ramsey SD; Nettleman MD
    Med Decis Making; 1992; 12(2):142-8. PubMed ID: 1573981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pharmacoeconomics of HIV disease.
    Lynn LA; Schulman KA; Eisenberg JM
    Pharmacoeconomics; 1992 Mar; 1(3):161-74. PubMed ID: 10147027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The costing of HIV/AIDS--without a clue?
    van der Linde I
    S Afr Med J; 1999 Jan; 89(1):33-4. PubMed ID: 10070404
    [No Abstract]   [Full Text] [Related]  

  • 11. The cost-effectiveness of treatment with lamivudine and zidovudine compared with zidovudine alone: a comparison of Markov model and trial data estimates.
    Mauskopf J; Lacey L; Kempel A; Simpson K
    Am J Manag Care; 1998 Jul; 4(7):1004-12. PubMed ID: 10181990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective evaluation of the cost effectiveness of adding lamivudine to zidovudine-containing antiretroviral treatment regimens in HIV infection. European perspective.
    Lacey L; Youle M; Trueman P; Staszewski S; Schrappe M; Behrens M
    Pharmacoeconomics; 1999; 15 Suppl 1():39-53. PubMed ID: 10537441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient classification and cost analysis of AIDS and HIV: the case of Belgium.
    De Graeve D; Lescrauwaet B; Nonneman W
    Health Policy; 1997 Feb; 39(2):93-106. PubMed ID: 10165046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of long term zidovudine therapy and Pneumocystis carinii prophylaxis on HIV disease. A review of the literature.
    Hoover DR
    Drugs; 1995 Jan; 49(1):20-36. PubMed ID: 7705214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The costs of treating HIV-infected children in Abidjan, Ivory Coast, 1996-1997].
    Giraudon I; Leroy V; Msellati P; Elenga N; Ramon R; Welffens-Ekra C; Dabis F
    Sante; 1999; 9(5):277-81. PubMed ID: 10657769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An evaluation of the cost effectiveness of adding lamivudine to zidovudine-containing regimens in HIV infection. Canadian perspective.
    Lacey L; Hopkinson PK; Montaner J; Leblanc F; Gill MJ
    Pharmacoeconomics; 1999; 15 Suppl 1():55-66. PubMed ID: 10537442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Zidovudine. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.
    Wilde MI; Langtry HD
    Drugs; 1993 Sep; 46(3):515-578. PubMed ID: 7693435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modeling the use of triple combination therapy in five countries: nevirapine, Zidovudine, and Didanosine.
    Biddle AK; Simpson KN
    Value Health; 2000; 3(3):186-201. PubMed ID: 16464183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis of emtricitabine/tenofovir versus lamivudine/zidovudine, in combination with efavirenz, in antiretroviral-naive, HIV-1-infected patients.
    Sánchez-de la Rosa R; Herrera L; Moreno S
    Clin Ther; 2008 Feb; 30(2):372-81. PubMed ID: 18343275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incremental cost-effectiveness of two zidovudine regimens to prevent perinatal HIV transmission in the United States.
    Pinkerton SD; Holtgrave DR; Layde PM
    Prev Med; 2000 Jan; 30(1):64-9. PubMed ID: 10642461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.